Although PALA [N-(phosphonacetyl)-l-aspartate], a pyrimidine nucleotide synthesis and CAD inhibitor, has been shown to sensitize tumor cells to chemotherapy in preclinical models, unfortunately, clinical trials did not support its use for breast cancer due to low efficacy and cytotoxicity [226,227]. This evidence concerns the gene CAD and neoplasm.